🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Doximity shares get price target bump by Evercore ISI

EditorAhmed Abdulazez Abdulkadir
Published 05/17/2024, 05:10 AM
DOCS
-

On Friday, Evercore ISI updated its price target for Doximity Inc (NYSE: NYSE:DOCS), a digital platform for medical professionals, raising it to $29 from $28. The firm has maintained an "In Line" rating for the stock. The adjustment follows Doximity's recent performance, which was noted to be solid, especially considering the deteriorating investor expectations prior to the company's earnings report.

According to the firm, Doximity has consistently shown profitability, even though its growth outlook might be slightly slower than what analysts had anticipated. The company's client portal, which is gaining traction with the launch of its reporting tools, is expected to enter the next phase of development. This phase will include purchasing capabilities and pricing tools, projected to be launched within this quarter.

Evercore ISI also highlighted that Doximity provided additional clarity regarding why deferred revenues might not be the most accurate metric for evaluating the company's performance. This information can be found in Doximity's revenue recognition and billing FAQ.

The firm's analyst pointed out that while there is an anticipation of a post-earnings re-rating of Doximity's stock, the decision to maintain the "In Line" rating is influenced by a combination of factors. These include the slightly lower top-line growth forecast, as well as uncertainties in the macroeconomic environment that could potentially impact advertising demand.

This is particularly relevant for upsells and the upcoming renewal cycle, which are important revenue streams for Doximity. The new price target of $29 is based on approximately 21 times the company's projected CY24 EBITDA.

InvestingPro Insights

In light of Evercore ISI's recent price target update for Doximity Inc (NYSE: DOCS), a deeper dive into the company's financial health and market performance reveals several key insights. Doximity's aggressive share buyback strategy, as noted in an InvestingPro Tip, is a strong signal of management's confidence in the company's value. Additionally, the company's robust gross profit margin of 88.94% for the last twelve months as of Q3 2023, coupled with a substantial operating income margin of 35.01%, underscores its efficiency and profitability in operations.

InvestingPro Data also shows that Doximity holds a market capitalization of $4.43 billion and is trading at a high earnings multiple, with a P/E ratio of 33.01. Despite this, analysts have a positive outlook, predicting the company to be profitable this year. This aligns with the reported revenue growth of 16.58% and EBITDA growth of 36.21% in the same period, indicating a strong upward trajectory for the company's financial performance.

For readers interested in a deeper analysis, there are additional InvestingPro Tips available, including insights into Doximity's cash versus debt position and its liquidity. To explore these valuable tips and make more informed investment decisions, consider subscribing to InvestingPro using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.